Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pilarquim (shanghai) co ltd - glyphosate present as the isopropylamine salt - soluble concentrate - glyphosate present as the isopropylamine salt glycine active 450.0 g/l - herbicide

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pilarquim (shanghai) co ltd - 2,4-d present as the dimethylamine and diethanolamine sa - soluble concentrate - 2,4-d present as the dimethylamine and diethanolamine sa - phenoxy acids-2,4-d - active - 625.0 - g/l - herbicide

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pilarquim(shanghai) co., ltd - lambda-cyhalothrin - capsule suspension - lambda-cyhalothrin pyrethroid active 250.0 g/l - insecticide

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pilarquim(shanghai) co., ltd - chlorothalonil - suspension concentrate - chlorothalonil benzene active 720.0 g/l - fungicide

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

alpha-cypermethrin 10% w/w ec

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

glyphosate ipa w/w sl 41%

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - vemurafenib 240mg (as a co-precipitate with hypromellose acetate succinate (800 mg total));  ;   - film coated tablet - 240 mg - active: vemurafenib 240mg (as a co-precipitate with hypromellose acetate succinate (800 mg total))     excipient: colloidal silicon dioxide croscarmellose sodium hyprolose iron oxide red macrogol 3350 magnesium stearate polyvinyl alcohol purified talc titanium dioxide - indicated for the treatment of unresectable stage iiic or stage iv metastatic melanoma positive for the braf v600 mutation.

Israel - engelsk - Ministry of Health

roche pharmaceuticals (israel) ltd - vemurafenib - film coated tablets - vemurafenib 240 mg - vemurafenib - vemurafenib - zelboraf is indicated for the treatment of brafv600 mutation-positive unresectable or metastatic melanoma.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dabrafenib mesilate 59.25mg equivalent to dabrafenib 50 mg;  ;   - capsule - 50 mg - active: dabrafenib mesilate 59.25mg equivalent to dabrafenib 50 mg     excipient: colloidal silicon dioxide hypromellose iron oxide red magnesium stearate microcrystalline cellulose purified water titanium dioxide - tafinlar is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma. tafinlar in combination with trametinib is indicated for the treatment of patients with unresectable or metastatic melanoma with a braf v600 mutation. tafinlar in combination with mekinist, is indicated for the adjuvant treatment of patients with stage iii melanoma with a braf v600 mutation, following complete resection.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dabrafenib mesilate 88.88mg equivalent to dabrafenib 75 mg;  ;   - capsule - 75 mg - active: dabrafenib mesilate 88.88mg equivalent to dabrafenib 75 mg     excipient: colloidal silicon dioxide hypromellose iron oxide red magnesium stearate microcrystalline cellulose purified water titanium dioxide - tafinlar is indicated for the treatment of patients with braf v600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma. tafinlar in combination with trametinib is indicated for the treatment of patients with unresectable or metastatic melanoma with a braf v600 mutation. tafinlar in combination with mekinist, is indicated for the adjuvant treatment of patients with stage iii melanoma with a braf v600 mutation, following complete resection.